Serum IL-33 Levels Are Raised in Patients with Systemic Sclerosis: Association with Extent of Skin Sclerosis and Severity of Pulmonary Fibrosis

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2011 Jan 20

PMID 21246230

Citations 56

Authors

Koichi Yanaba

Ayumi Yoshizaki

Yoshihide Asano

Takafumi Kadono

Shinichi Sato

Affiliations

Soon will be listed here.

Abstract

To determine serum interleukin-33 (IL-33) levels and their associations with clinical parameters in patients with systemic sclerosis (SSc). Serum IL-33 levels were examined by enzyme-linked immunosorbent assay in 69 patients with SSc and 30 healthy individuals. In a retrospective longitudinal study, sera from 14 patients with SSc were analyzed (follow-up, 1-7 years). Serum IL-33 levels were elevated in SSc patients (261.7 ± 141.9 pg/ml) compared with healthy individuals (174.9 ± 72.4 pg/ml; P < 0.001). Patients with diffuse cutaneous SSc had higher levels of IL-33 (287.5 ± 146.6 pg/ml) than those with limited cutaneous SSc (221.5 ± 126.5 pg/ml; P < 0.05). Pulmonary fibrosis and decreased forced vital capacity were more commonly found in patients with elevated IL-33 levels than in those with normal IL-33 levels. IL-33 levels correlated positively with the extent of skin sclerosis, and inversely with percent predicted forced vital capacity. IL-33 levels were increased in SSc patients and correlated with the extent of skin sclerosis and the severity of pulmonary fibrosis. Therefore, IL-33 possibly plays a role in cutaneous and pulmonary fibrosis in SSc patients.

Citing Articles

Characterization of Endothelial Cell Subclusters in Localized Scleroderma Skin with Single-Cell RNA Sequencing Identifies NOTCH Signaling Pathway.

Hutchins T, Sanyal A, Esencan D, Lafyatis R, Jacobe H, Torok K Int J Mol Sci. 2024; 25(19).

PMID: 39408800 PMC: 11477421. DOI: 10.3390/ijms251910473.

The production, function, and clinical applications of IL-33 in type 2 inflammation-related respiratory diseases.

Gu S, Wang R, Zhang W, Wen C, Chen C, Liu S Front Immunol. 2024; 15:1436437.

PMID: 39301028 PMC: 11410612. DOI: 10.3389/fimmu.2024.1436437.

The role of interleukin-33 in organ fibrosis.

Di Carmine S, Scott M, McLean M, McSorley H Discov Immunol. 2024; 1(1):kyac006.

PMID: 38566909 PMC: 10917208. DOI: 10.1093/discim/kyac006.

Association of serum Ly6/PLAUR domain-containing protein 1 levels with skin sclerosis in systemic sclerosis.

Sugimori A, Omori I, Iwasawa O, Saito H, Nakajima H, Matsuno A Sci Rep. 2024; 14(1):5572.

PMID: 38448661 PMC: 10918060. DOI: 10.1038/s41598-024-56221-z.

[Skin fibrosis : Novel insights in pathophysiology and treatment].

Willenborg S, Satzinger S, Eming S Dermatologie (Heidelb). 2024; 75(3):218-224.

PMID: 38351374 DOI: 10.1007/s00105-024-05299-7.

References

Clements P, Lachenbruch P, Seibold J, Zee B, Steen V, Brennan P . Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993; 20(11):1892-6. View

FLEISCHMAJER R, Perlish J, Reeves J . Cellular infiltrates in scleroderma skin. Arthritis Rheum. 1977; 20(4):975-84. DOI: 10.1002/art.1780200410. View

Gillery P, Fertin C, Nicolas J, Chastang F, Kalis B, Banchereau J . Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis. FEBS Lett. 1992; 302(3):231-4. DOI: 10.1016/0014-5793(92)80448-p. View

Sato S, Ihn H, Kikuchi K, Takehara K . Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum. 1994; 37(3):391-4. DOI: 10.1002/art.1780370313. View

Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S . Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol. 2006; 33(2):275-84. View

Xu D, Jiang H, Kewin P, Li Y, Mu R, Fraser A . IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A. 2008; 105(31):10913-8. PMC: 2491487. DOI: 10.1073/pnas.0801898105. View

White B . Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am. 1996; 22(4):695-708. DOI: 10.1016/s0889-857x(05)70296-9. View

Moussion C, Ortega N, Girard J . The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?. PLoS One. 2008; 3(10):e3331. PMC: 2556082. DOI: 10.1371/journal.pone.0003331. View

Komai-Koma M, Xu D, Li Y, McKenzie A, McInnes I, Liew F . IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007; 37(10):2779-86. DOI: 10.1002/eji.200737547. View

10.

Chizzolini C . T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol. 2000; 21(4):431-50. DOI: 10.1007/s002810000035. View

11.

. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90. DOI: 10.1002/art.1780230510. View

12.

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan T . IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23(5):479-90. DOI: 10.1016/j.immuni.2005.09.015. View

13.

Roumm A, Whiteside T, Medsger Jr T, Rodnan G . Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984; 27(6):645-53. DOI: 10.1002/art.1780270607. View

14.

Famularo G, Procopio A, Giacomelli R, Danese C, Sacchetti S, PEREGO M . Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol. 1990; 81(3):368-72. PMC: 1534974. DOI: 10.1111/j.1365-2249.1990.tb05340.x. View

15.

Manetti M, Ibba-Manneschi L, Liakouli V, Guiducci S, Milia A, Benelli G . The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis. 2009; 69(3):598-605. DOI: 10.1136/ard.2009.119321. View

16.

LeRoy E, Black C, FLEISCHMAJER R, Jablonska S, Krieg T, Medsger Jr T . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202-5. View

17.

Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer C, Viatte S . Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009; 60(3):738-49. DOI: 10.1002/art.24305. View

18.

Steen V, Powell D, Medsger Jr T . Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988; 31(2):196-203. DOI: 10.1002/art.1780310207. View

19.

Sato S . Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol. 1999; 11(6):503-7. View

20.

Needleman B, Wigley F, Stair R . Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum. 1992; 35(1):67-72. DOI: 10.1002/art.1780350111. View